FDA.reportPublic FDA data

Mvasi 400 MG per 16 ML Injection

RxCUI
2046145
RxNorm name
Mvasi 400 MG per 16 ML Injection
Display name
Mvasi 400 MG per 16 ML Injection
Full name
Mvasi 400 MG per 16 ML Injection
Term type
SY
Status
DailyMed mapping
Updated
2026-06-04 23:38:46

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
761028Mvasibevacizumab-awwb351(k) BiosimilarRx2026-07-01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
MVASIBEVACIZUMAB-AWWBAmgen, Inc0a562b4e-67ce-4bab-852c-d9ee71e55fb82026-06-23Warnings, Adverse reactionsExact identifier
rxcui: 2046145

DailyMed RxNorm Mappings#

Set ID, RxNorm string, TTY table
Set IDRxNorm stringTTYSPL versionLabelEffective
0a562b4e-67ce-4bab-852c-d9ee71e55fb8Mvasi 400 MG per 16 ML InjectionSY22These highlights do not include all the information needed to use MVASI safely and effectively. See full prescribing information for MVASI. MVASI ® (bevacizumab-awwb) injection, for intravenous use Initial U.S. Approval: 2017 MVASI (bevacizumab-awwb) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between the20260310
0a562b4e-67ce-4bab-852c-d9ee71e55fb8MVASI 400 MG in 16 ML InjectionPSN22These highlights do not include all the information needed to use MVASI safely and effectively. See full prescribing information for MVASI. MVASI ® (bevacizumab-awwb) injection, for intravenous use Initial U.S. Approval: 2017 MVASI (bevacizumab-awwb) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between the20260310
0a562b4e-67ce-4bab-852c-d9ee71e55fb816 ML Mvasi 25 MG/ML InjectionSY22These highlights do not include all the information needed to use MVASI safely and effectively. See full prescribing information for MVASI. MVASI ® (bevacizumab-awwb) injection, for intravenous use Initial U.S. Approval: 2017 MVASI (bevacizumab-awwb) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between the20260310
0a562b4e-67ce-4bab-852c-d9ee71e55fb816 ML bevacizumab-awwb 25 MG/ML Injection [Mvasi]SBD22These highlights do not include all the information needed to use MVASI safely and effectively. See full prescribing information for MVASI. MVASI ® (bevacizumab-awwb) injection, for intravenous use Initial U.S. Approval: 2017 MVASI (bevacizumab-awwb) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between the20260310